Groups Parameters Total lipids (g/L) Triglycerides (mg/dl) Total cholesterol (mg/dl) LDL- cholesterol (mg/dl) HDL- cholesterol (mg/dl) vLDL- cholesterol (mg/dl) LDL/ HDL Total chol./ HDL HMGCo-A/ mevalonate
Normal 3.46±0.18b 37.48±1.31b 68.61±3.55b 27.84±0.28b 33.27±1.57a 7.49±0.26b 0.88±0.05b 2.07±0.09b 1.36±0.04b
Diabetic control 4.82±0.34a 46.35±2.14a 80.12±1.77a 42.83±1.76a 28.14±1.24a 9.27±0.43a 1.54±0.11a 2.87±0.18a 1.59±0.02a
Diabetic treated with 4b 3.47±0.07b 36.50±081b 76.13±2.47ab 42.62±1.83a 27.67±2.65a 7.30±0.16b 1.58±0.09a 2.85±0.21a 1.60±0.03a
F-probability P<0.01 P<0.001 P<0.05 P<0.001 P>0.05 P<0.001 P<0.001 P<0.01 P<0.001
LSD at 5% level 0.68 4.59 8.13 4.45 - 0.92 0.256 0.511 0.103
LSD at 1% level 0.94 6.35 11.24 6.16 - 1.27 0.355 0.706 0.144
Table 9: Effect of pyrimido[1,6-a]quinazoline derivative 4b on serum lipid profile in n5-STZ induced type 2 diabetic female rats.